Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib

Muhammad Latif, Sana Mazhar, Mussarat Tasleem, Abdulmajeed Alqurashi, Muhammad Arfan, Zaman Ashraf, Muhammad Sohail Zafar · 2026

Read Advances in PARP Inhibition in Improving Outcomes of Breast Cancer, Ovarian Cancer, and Other Solid Tumors: Journey of Discovery, Development, and Clinical Updates of Talazoparib by Muhammad Latif, Sana Mazhar, Mussarat Tasleem, Abdulmajeed Alqurashi, Muhammad Arfan, Zaman Ashraf, Muhammad Sohail Zafar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13158130.txt.

Description

Muhammad Latif and co-authors review a class of cancer drugs called PARP inhibitors, with a focus on one drug, talazoparib, published in 2026. Blocking PARP, a protein that helps repair DNA, has become a leading approach in cancer care. Several drugs of this kind have shown gains in trials for ovarian, breast, and other solid tumors.

The review traces the role of the BRCA genes in these cancers and the milestones that led to this drug class. It surveys drugs at many stages of development, then details the discovery and current status of talazoparib. That drug is used for advanced breast cancer in patients with inherited BRCA faults. Trials from early to late phase are covered, along with what the drug may offer in practice.

Catalog record

CREATORMuhammad Latif, Sana Mazhar, Mussarat Tasleem, Abdulmajeed Alqurashi, Muhammad Arfan, Zaman Ashraf, Muhammad Sohail Zafar
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE161 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13158130

Browse the full library · About the Tower of Babel